Embecta Corp. (EMBC) — Inside-Filings

Sentiment-Signal

13,4

Stark Bearisch

Composite Score (0–100)

Insider (25%)

Keine Insider-Käufe

Institutionell (22,5%)

Keine neuen Positionen

Aktivist (12,5%)

Kein 13D/13G

Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)

Score-Verlauf (90 Tage)

Kritische 8-K Meldungen

Datum	Meldung	Schwere	Filing	Auszug
17.11.2025	Item 5.02 — Abgang Schlüsselpersonen	HOCH	SEC	Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Offic
02.12.2024	Item 5.02 — Abgang Schlüsselpersonen	HOCH	SEC	Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Com
12.08.2024	Item 5.02 — Abgang Schlüsselpersonen	HOCH	SEC	Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
05.07.2023	Item 5.02 — Abgang Schlüsselpersonen	HOCH	SEC	ction 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appoi

Stammdaten

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing their diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is based in Parsippany, New Jersey. Embecta Corp.(NasdaqGS:EMBC) operates independently of Becton, Dickinson and Company as of April 1, 2022.

Unternehmen & Branche

Name	Embecta Corp.
Ticker	EMBC
CIK	0001872789
Boerse	US
Sektor	Healthcare
Industrie	Drug Manufacturers - Specialty & Generic
SIC	3841 · Surgical & Medical Instruments & Apparatus

Wertpapier & Kennzahlen

CUSIP	–
ISIN	–
Typ	Common Stock
Marktkapitalisierung	514,7 Mio. USD
Beta	1,10
Dividendenrendite	0,60 %

Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »

Finanzkennzahlen (SEC XBRL)

Periode	Filing	Umsatz	Nettoergebnis	EPS	Aktiva	Eigenkapital
2025-12-31	10-Q	261,200,000	44,100,000	0.74	1,063,700,000	-613,100,000
2025-09-30	10-K	1,080,400,000	95,400,000	1.62	1,090,900,000	-650,600,000
2025-06-30	10-Q	295,500,000	45,500,000	0.78	1,157,300,000	-669,600,000
2025-03-31	10-Q	259,000,000	23,500,000	0.40	1,120,200,000	-736,200,000
2024-12-31	10-Q	261,900,000	0	0.00	1,149,500,000	-768,800,000
2024-09-30	10-K	1,123,100,000	78,300,000	1.34	1,285,300,000	-738,300,000
2024-06-30	10-Q	272,500,000	14,700,000	0.25	1,267,500,000	-763,700,000
2024-03-31	10-Q	287,200,000	28,900,000	0.50	1,199,600,000	-769,600,000
2023-12-31	10-Q	277,300,000	20,100,000	0.35	1,217,800,000	-793,500,000
2023-09-30	10-K	1,120,800,000	70,400,000	1.22	1,214,400,000	-821,700,000
2023-06-30	10-Q	286,100,000	15,200,000	0.26	1,252,100,000	-809,400,000
2023-03-31	10-Q	277,100,000	14,000,000	0.24	1,210,000,000	-822,600,000
2022-12-31	10-Q	275,700,000	35,200,000	0.61	1,196,900,000	-836,100,000
2022-09-30	10-K	1,129,500,000	223,600,000	3.89	1,086,400,000	-891,400,000
2022-06-30	10-Q	291,100,000	62,400,000	1.07	1,049,800,000	-847,600,000
2022-03-31	10-Q	274,500,000	79,600,000	1.38	833,500,000	-967,500,000
2021-12-31	10-Q	289,300,000	98,800,000	1.73	739,900,000	550,500,000
2021-09-30	10-K	1,165,300,000	414,800,000	7.28	788,000,000	594,300,000
2021-06-30	10-Q	295,000,000	104,700,000	1.81		576,700,000
2021-03-31	10-Q	284,200,000	107,900,000	1.87		580,700,000

Fondsaktivität (Vorquartalsvergleich)

Keine Fondsdaten für dieses Unternehmen vorhanden.

Insider-Transaktionen (12 Monate)

Keine Insider-Käufe/Verkäufe in den letzten 12 Monaten.

Top-Fondshalter

Keine Fondsdaten zu dieser Aktie vorhanden.